Roche launches newborn screening test for three severe genetic conditions

Roche's new PCR kit screens newborns for SMA, SCID, and sickle cell disease in one workflow.

Image: Illustrative figure from a related study: Pugner B et al., Sensors (Basel, Switzerland) (2026), CC BY 4.0

Source: The Corry Journal, by Roche (September 30, 2026). AI-generated summary by biochip.com, published . Not independently reviewed.

Key takeaways

  • TIB MOLBIOL launched a LightMix kit that screens newborns for SMA, SCID, and sickle cell disease simultaneously.
  • The IVDR-approved kit runs on established Roche LightCycler systems for private and academic hospital laboratories.
  • The launch does not establish clinical performance metrics, screening accuracy, or adoption by national newborn screening programs.

Roche subsidiary TIB MOLBIOL has launched a single newborn screening kit designed to detect signs of three serious inherited conditions at once: spinal muscular atrophy, severe combined immunodeficiency, and sickle cell disease. The LightMix Newborn TREC/SMN1/HBB kit is an in vitro diagnostic test for countries that accept the CE mark, and Roche says it is approved under the European Union's In Vitro Diagnostic Regulation. By running on established LightCycler systems, the kit is intended to fit into hospital laboratory workflows rather than requiring a new instrument. The aim is to identify affected infants before symptoms cause permanent harm and prompt confirmatory testing and treatment.

Three conditions, one screening workflow

The kit combines tests for three distinct genetic diseases. Spinal muscular atrophy, or SMA, damages nerve cells in the spinal cord and progressively weakens muscles. The test targets loss of exon 7 in the survival motor neuron 1 gene, known as SMN1, a characteristic genetic cause of the condition.

For severe combined immunodeficiency, or SCID, the kit measures T-cell receptor excision circles, abbreviated TREC. These are small pieces of DNA associated with the production of T cells, immune cells that help the body fight infection. Low or absent TREC signals can flag infants who may lack a functioning immune system and need urgent follow-up.

The third target is sickle cell disease, or SCD, an inherited disorder linked to mutations in the HBB gene. In SCD, red blood cells can become stiff and sickle-shaped, which can block blood vessels and break down early. The kit's combined TREC, SMN1, and HBB design allows laboratories to screen for all three conditions in the same offering.

Why early results matter

Newborn screening is not the final diagnosis. It is an early warning system, much like a smoke alarm that signals a problem before the fire spreads. Roche positions the assay as a first-tier screen that triggers immediate confirmatory testing and therapeutic decisions when a result indicates elevated risk.

That timing matters particularly for SMA, where treatment can begin before symptoms appear. Roche says earlier recognition may help prevent severe nerve damage and disability. For SCD, timely care can include preventive penicillin and specialized immunizations to reduce the danger of severe infections in infancy.

SCID has especially urgent consequences because affected babies have few or no functioning T cells. Without prompt intervention, the condition can be fatal in the first year or two of life. Detecting SCID before dangerous infections emerge can allow clinicians to consider treatments such as bone marrow transplantation.

Built for existing molecular laboratories

The LightMix kit runs on Roche's established LightCycler systems, instruments that use polymerase chain reaction, or PCR, to amplify and detect selected genetic material. PCR works like making enough copies of a faintly printed page to read it clearly: each cycle amplifies a targeted DNA sequence until the system can measure it.

TIB MOLBIOL supplies molecular PCR assays as ready-to-use and modular kits for medical diagnostics, research, and industrial applications. Roche says the new test offers private and academic hospital laboratories a ready-to-use route to add combined screening for SMA, SCID, and SCD within their existing workflows.

Why This Matters

Newborn screening programs need tests that are accurate, practical, and fast enough to guide action while an infant is still well. Combining three clinically consequential conditions in one molecular kit could simplify laboratory operations where the relevant LightCycler platform and regulatory pathway are already in place. The next practical question will be how individual laboratories and national screening programs incorporate the assay into their own testing, confirmation, and care pathways.

Topics: Diagnostics & precision medicine · Heart & vascular health · Infectious diseases

Start here: What is a biochip?